Functional changes in the ageing kidney: Is there a role for asymmetric dimethylarginine?

Nephrology Dialysis Transplantation

Volumn 18, Issue 7, 2003, Pages 1245-1248

  Kielstein, Jan T ^a   Bode Böger, Stefanie M ^b   Haller, Hermann ^a   Fliser, Danilo ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Elderly; Glomerulosclerosis; Hypertension; Renal perfusion; Renovascular esitance

Indexed keywords

DIMETHYLARGININASE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE SYNTHASE INHIBITOR;

AGE; AGED; AGING; BLOOD PRESSURE; BLOOD VESSEL TONE; CLINICAL STUDY; COMORBIDITY; DISEASE ASSOCIATION; EDITORIAL; ENDOTHELIUM INJURY; ENZYME ACTIVITY; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY BLOOD FLOW; KIDNEY BLOOD VESSEL; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; KIDNEY PERFUSION; KIDNEY VASCULAR RESISTANCE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SENESCENCE; VASOCONSTRICTION;

EID: 0037677194     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfg183     Document Type: Editorial

References (28)

1. Lindeman RD, Tobin JD, Shock NW. Association between blood pressure and the rate of decline in renal function with age. Kidney Int 1984; 26: 861-868
2. Kasiske BL. Relationship between vascular disease and age-associated changes in the human kidney. Kidney Int 1987; 31: 1153-1159
3. Fliser D, Franek E, Joest M, Block S, Mutschler E, Ritz E. Renal function in the elderly: impact of hypertension and cardiac function. Kidney Int 1997; 51: 1196-1204
4. Bleyer AJ, Shemanski LR, Burke GL, Hansen KJ, Appel RG. Tobacco, hypertension, and vascular disease: risk factors for renal function decline in an older population. Kidney Int 2000; 57: 2072-2079
5. Ribstein J, Du Cailar G, Mimran A. Glucose tolerance and age-associated decline in renal function of hypertensive patients. J Hypertens 2001; 19: 2257-2264
6. Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 1985; 33: 278-285
7. Fliser D, Ritz E. The relationship between hypertension and renal function and its therapeutic implications in the elderly. Gerontology 1998; 44: 123-131
8. Schmieder RE, Schachinger H, Messerli FH. Accelerated decline in renal perfusion with aging in essential hypertension. Hypertension 1994; 23: 351-357
9. Cody RJ, Torre S, Clark M, Pondolfino K. Age-related hemodynamic, renal, and hormonal differences among patients with congestive heart failure. Arch Intern Med 1989; 149: 1023-1028
10. Fliser D, Zeier M, Nowack R, Ritz E. Renal functional reserve in healthy elderly subjects. J Am Soc Nephrol 1993; 3: 1371-1377
11. Higashi Y, Oshima T, Ozono R, Matsuura H, Kajiyama G. Aging and severity of hypertension attenuate endothelium-dependent renal vascular relaxation in humans. Hypertension 1997; 30: 252-258
12. Fuiano G, Sund S, Mazza G et al. Renal hemodynamic response to maximal vasodilating stimulus in healthy older subjects. Kidney Int 2001; 59: 1052-1058
13. Sabbatini M, Sansone G, Uccello F et al. Functional versus structural changes in the pathophysiology of acute ischemic renal failure in aging rats. Kidney Int 1994; 45: 1355-1361
14. Lahera V, Salom MG, Miranda-Guardiola F, Moncada S, Romero JC. Effects of NG-nitro-L-arginine methyl ester on renal function and blood pressure. Am J Physiol 1991; 261: F1033-F1037
15. Broere A, Van Den Meiracker AH, Boomsma F, Derkx F, Man in't Veld AJ, Schalekamp MADH. Human renal and systemic hemodynamic, natriuretic, and neurohumoral responses to different doses of L-NAME. Am J Physiol 1998; 275: F870-F877
16. Granger JP, Alexander BT. Abnormal pressure-natriuresis in hypertension: role of nitric oxide. Acta Physiol Scand 2000; 68: 161-168
17. Miyazaki H, Matsuoka H, Cooke JP et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 1999; 99: 1141-1146
18. Kielstein JT, Boger RH, Bode-Boger SM et al. Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol 2002; 13: 170-176
19. Cooke JP. Does ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Biol 2000; 20: 2032-2037
20. Tojo A, Welch WJ, Bremer V et al. Colocalization of demethylating enzymes and NOS and functional effects of methylarginines in rat kidney. Kidney Int 1997; 52: 1593-1601
21. Leiper J, Murray-Rust J, McDonald M, Vallance P. S-nitrosylation of dimethylarginine dimethylamino-hydrolase regulates enzyme activity: further interaction between nitric oxide synthase and dimethylarginine dimethylaminohydrolase. Proc Natl Acad Sci USA 2002; 99: 13527-13532
22. Stuhlinger MC, Abbasi F, Chu JW et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. J Am Med Assoc 2002; 287: 1420-1426
23. Xiong Y, Yuan LW, Deng HW, Li YJ, Chen BM. Elevated serum endogenous inhibitor of nitric oxide synthase and endothelial dysfunction in aged rats. Clin Exp Pharmacol Physiol 2001; 28: 842-847
24. Kielstein JT, Bode-Böger SM, Frölich C, Ritz E, Haller H, Fliser D. Asymmetric dimethylarginine blood pressure and renal perfusion in elderly subjects. Circulation 2003; 107: 1891-1895
25. Zoccali C, Bode-Boger S, Mallamaci F et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001; 358: 2113-2117
26. Vallance P. Importance of asymmetrical dimethylarginine in cardiovascular risk. Lancet 2001; 358: 2096-2097
27. Gardiner SM, Kemp PA, Bennett T, Palmer RM, Moncada S. Regional and cardiac haemodynamic effects of NG, NG,dimethyl-L-arginine and their reversibility by vasodilators in conscious rats. Br J Pharmacol 1993; 110: 1457-1464
28. Kielstein JT, Impraim B, Simmel S et al. Asymmetric dimethyl-arginine (ADMA) is a potent and long-lasting inhibitor of nitric oxide synthase. Kidney Blood Press Res 2002; 25: 130A